Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis

Chung Yin Stanley Chan, John C. Browning, Fiona Larsen, Sylvia Hsu

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Infliximab is a chimeric monoclonal antibody that selectively blocks tumor necrosis factor-alpha (TNF-α). It is indicated for the treatment of numerous inflammatory diseases, including rheumatoid arthritis, Crohn disease, ulcerative colitis, ankylosing spondyilitis, and psoriatic arthritis. Infliximab has also been shown to be a well tolerated and highly effective treatment for psoriatic skin lesions. We report an interesting case of unexpected, newonset psoriasis in a patient on infliximab for rheumatoid arthritis.

Original languageEnglish (US)
Article number12
JournalDermatology online journal
Volume14
Issue number9
StatePublished - Sep 1 2008
Externally publishedYes

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis'. Together they form a unique fingerprint.

  • Cite this